FDA isn't lifting the clinical hold on Solid Bio's Duchenne MD gene therapy just yet — but is there a silver lining?
It may now be close to a year before Solid Bio can resume human testing on its lead gene therapy program.
The clinical hold that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
